HBMN:SWX
HBM Healthcare Investments AG
CHF 249.50
0.00%
(0.00) 1D
Jul 20, 5:31:25 PM GMT+2 · CHF
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HBMN...
Mkt. cap
1.65B
Avg. vol.
4.75K
Volume
0.00
Dividend
3.61%
Quarterly dividend
CHF 2.25
Ex-dividend date
Jun 17, 2026
P/E ratio
6.12
52-wk high
CHF 258.00
52-wk low
CHF 158.00
EPS
CHF 40.74
Shares outstanding
6.62M
Mkt. cap
1.65B
Avg. vol.
4.75K
Volume
0.00
Dividend
3.61%
Quarterly dividend
CHF 2.25
Ex-dividend date
Jun 17, 2026
P/E ratio
6.12
52-wk high
CHF 258.00
52-wk low
CHF 158.00
EPS
CHF 40.74
Shares outstanding
6.62M
News stories
From sources across the web
Kalkine Media
·
26 minutes ago
UnitedHealth Group (NYSE:UNH) Expands S&P 500 Healthcare Reach
MarketBeat
·
36 minutes ago
iQIYI, Inc. Sponsored ADR (NASDAQ:IQ) Receives Average Rating of "Hold" from Analysts
Moomoo
·
48 minutes ago
[Stocks to Watch] The Nikkei Average approaches a 2,000-yen gain, driven higher by rising Nasdaq 100 futures.
Investor's Business Daily
·
4 hours ago
Dow Jones Futures: Trump Comments Spark Stock Market Losses; Elon Musk-Led SpaceX, Tesla Tumble
Profile
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
About HBM Healthcare Investments AG
CEO-
Employees-
FoundedJul 12, 2001
HeadquartersZug, Zug, Switzerland
SectorCapital market
Websitehbmhealthcare.com
AI content may include mistakes. Learn more